{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:16:50Z","timestamp":1791922610784,"version":"4.3.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinejcf.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.cardfail.2025.10.006","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T20:49:36Z","timestamp":1762634976000},"page":"1767-1777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Demographics and Trends in Reported Amyloidosis-related Mortality in the United States, 1999\u22122023"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2021-1660","authenticated-orcid":false,"given":"VIKASH","family":"JAISWAL","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YUSRA","family":"MASHKOOR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KRITI","family":"KALRA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DANISHA","family":"KUMAR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FAKHAR","family":"LATIF","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YUSRA MINAHIL","family":"NASIR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GREGG C.","family":"FONAROW","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KEVIN M.","family":"ALEXANDER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ARMAN","family":"QAMAR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2025.10.006_bib0001","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1182\/hematology.2021000305","article-title":"AL amyloidosis: untangling new therapies","volume":"2021","author":"Bal","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0002","series-title":"StatPearls (Internet]","article-title":"Amyloidosis","author":"Bustamante","year":"2025"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0003","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","article-title":"Epidemiology of AL amyloidosis: a real-world study using US claims data","volume":"2","author":"Quock","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0004","doi-asserted-by":"crossref","first-page":"247","DOI":"10.5858\/arpa.2016-0102-RA","article-title":"Amyloidosis of the lung","volume":"141","author":"Khoor","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0005","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.028973","article-title":"Clinical penetrance of the transthyretin V122I variant in older black patients with heart failure: the SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) study","volume":"12","author":"Madhani","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0006","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamacardio.2018.2093","article-title":"Geographic disparities in reported US amyloidosis mortality from 1979 to 2015: potential underdetection of cardiac amyloidosis","volume":"3","author":"Alexander","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0007","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0008","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0009","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC State-of-the-Art Review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0010","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0011","unstructured":"Centers for Disease Control and Prevention, National Center for Health Statistics. Multiple cause of death 1999\u20132019 on CDC WONDER online Database, released in 2020. Data are from the Multiple Cause of Death Files, 1999\u20132019, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative. http:\/\/wonder.cdc.gov\/mcd-icd10.html"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0012","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet (London, England)"},{"issue":"3","key":"10.1016\/j.cardfail.2025.10.006_bib0013","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S2213-2600(19)30354-6","article-title":"Trends in mortality related to pulmonary embolism in the European Region, 2000-15: analysis of vital registration data from the WHO Mortality Database","volume":"8","author":"Barco","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0014","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1001\/jama.2019.16932","article-title":"Life expectancy and mortality rates in the United States, 1959\u20132017","volume":"322","author":"Woolf","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0015","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years","volume":"146","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0016","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1177\/2047487319877708","article-title":"Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings","volume":"27","author":"Vergaro","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0017","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejim.2024.01.001","article-title":"Breakthrough advances enhancing care in ATTR amyloid cardiomyopathy","volume":"123","author":"Porcari","year":"2024","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0018","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJMc1917321","article-title":"Epidemiologic and survival trends in amyloidosis, 1987\u20132019","volume":"382","author":"Ravichandran","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1026440","article-title":"Evolving trends in epidemiology and natural history of cardiac amyloidosis: 30-year experience from a tertiary referral center for cardiomyopathies","volume":"9","author":"Porcari","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0020","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/13506129.2021.2013193","article-title":"Describing mode of death in three major cardiac amyloidosis subtypes to improve management and survival","volume":"29","author":"Kharoubi","year":"2022","journal-title":"Amyloid"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0021","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/jcsm.13306","article-title":"Frailty and heart failure: State-of-the-art review","volume":"14","author":"Talha","year":"2023","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0022","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jchf.2020.12.005","article-title":"The impact of patients with cardiac amyloidosis in HFpEF trials","volume":"9","author":"Oghina","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0023","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.009038","article-title":"Proposed cardiac end points for clinical trials in immunoglobulin light chain amyloidosis: report from the amyloidosis forum cardiac working group","volume":"15","author":"Maurer","year":"2022","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0024","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.amjcard.2023.07.140","article-title":"Safety and efficacy of traditional heart failure therapies in patients with cardiac amyloidosis and heart failure","volume":"204","author":"Yan","year":"2023","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0025","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022859","article-title":"Lack of association between neurohormonal blockade and survival in transthyretin cardiac amyloidosis","volume":"10","author":"Cheng","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0026","first-page":"563","article-title":"Long-term efficacy of tafamidis in patients with transthyretin amyloid cardiomyopathy by National Amyloidosis Centre stage","volume":"26","author":"Damy","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0027","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jaccao.2024.12.005","article-title":"A multicenter study of contemporary long-term tafamidis outcomes in transthyretin amyloid cardiomyopathy","volume":"7","author":"Masri","year":"2025","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0028","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/ajh.27177","article-title":"Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment","volume":"99","author":"Gertz","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0029","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.122.009637","article-title":"Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"15","author":"Elliott","year":"2022","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0030","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1002\/ehf2.14337","article-title":"Patients with cardiac amyloidosis are at a greater risk of mortality and hospital readmission after acute heart failure","volume":"10","author":"Berthelot","year":"2023","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0031","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41408-020-00385-0","article-title":"Race\/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities","volume":"10","author":"Staron","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0032","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.amjms.2022.12.009","article-title":"Ethnic\/racial differences in risk factors and clinical outcomes among patients with amyloidosis","volume":"365","author":"Ream","year":"2023","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0033","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002558","article-title":"Transthyretin cardiac amyloidosis in black americans","volume":"9","author":"Shah","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0034","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41408-021-00466-8","article-title":"Racial disparities in patients diagnosed with light chain (AL) amyloidosis","volume":"11","author":"D'Souza","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0035","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/HCO.0000000000000855","article-title":"Racial and ethnic disparities in heart failure: current state and future directions","volume":"36","author":"Lewsey","year":"2021","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0036","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s12170-021-00670-y","article-title":"Racial and ethnic disparities in transthyretin cardiac amyloidosis","volume":"15","author":"Spencer-Bonilla","year":"2021","journal-title":"Curr Cardiovasc Risk Rep"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0037","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/eurheartj\/ehz173","article-title":"Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"43","author":"Damy","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0038","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10741-020-10010-8","article-title":"Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges","volume":"26","author":"Bruno","year":"2021","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0039","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jchf.2021.05.005","article-title":"Sex-related risk of cardiac involvement in hereditary transthyretin amyloidosis: insights from THAOS","volume":"9","author":"Caponetti","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0040","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/ejhf.2532","article-title":"Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies","volume":"24","author":"Aimo","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0041","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10741-023-10339-w","article-title":"Sex differences in transthyretin cardiac amyloidosis","volume":"29","author":"Aimo","year":"2024","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0042","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jchf.2021.09.010","article-title":"Overcoming the diagnostic pitfalls of women with cardiac amyloidosis","volume":"10","author":"Itzhaki Ben Zadok","year":"2022","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0043","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1161\/CIRCRESAHA.121.319900","article-title":"Heart failure subtypes and cardiomyopathies in women (published correction appears in Circ Res. 2022;130(6):e21.] (published correction appears in Circ Res. 2022;130(9):e25]","volume":"130","author":"DeFilippis","year":"2022","journal-title":"Circ Res."},{"key":"10.1016\/j.cardfail.2025.10.006_bib0044","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.3390\/jcm12062273","article-title":"Estimating the prevalence of cardiac amyloidosis in old patients with heart failure-barriers and opportunities for improvement: the PREVAMIC Study","volume":"12","author":"Ruiz-Hueso","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0045","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.863179","article-title":"Assessment and management of older patients with transthyretin amyloidosis cardiomyopathy: geriatric cardiology, frailty assessment and beyond","volume":"9","author":"Irabor","year":"2022","journal-title":"Front Cardiovasc Med."},{"key":"10.1016\/j.cardfail.2025.10.006_bib0046","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","article-title":"Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction (published correction appears in JAMA Cardiol. 2021 Dec 1;6(12):1469]","volume":"6","author":"AbouEzzeddine","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0047","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.amjcard.2023.07.023","article-title":"Adverse outcomes in hospitalizations for amyloid-related heart failure","volume":"203","author":"Appunni","year":"2023","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0048","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jaccao.2020.10.007","article-title":"Amyloidosis and 30-day outcomes among patients with heart failure: a nationwide readmissions database study","volume":"2","author":"Arora","year":"2020","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0049","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11739-025-03893-8","article-title":"Demographic and regional trends in systemic and cardiovascular amyloidosis-related mortality among older adults in the United States from 1999 to 2020","volume":"20","author":"Dhaliwal","year":"2025","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.cardfail.2025.10.006_bib0050","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916425005093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916425005093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:23:32Z","timestamp":1791879812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916425005093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1071916425005093"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2025.10.006","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Demographics and Trends in Reported Amyloidosis-related Mortality in the United States, 1999\u22122023","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiac Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2025.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}